MedTrace Logo

Single Ascending Dose Study With BPL-003 in Healthy Subjects

NCT05347849 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 62

Last updated 2024-03-18

No results posted yet for this study

Summary

The study will evaluate safety, tolerability and PK profile of BPL-003 in healthy subjects

Conditions

  • Pharmacokinetics in Healthy Adults

Interventions

DRUG

BPL-003

A single dose of BPL-003 will be administered intranasally

OTHER

Placebo

A single dose of placebo will be administered intranasally

Sponsors & Collaborators

  • Beckley Psytech Limited

    lead INDUSTRY

Principal Investigators

  • VP & Head of Clinical Development, PhD · Beckley Psytech Ltd

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
SEQUENTIAL

Eligibility

Min Age
25 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2022-02-14
Primary Completion
2024-01-19
Completion
2024-01-19

Countries

  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05347849 on ClinicalTrials.gov